| Style | Citing Format |
|---|---|
| MLA | Azizpour Y, et al.. "Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences." Journal of Biostatistics and Epidemiology, vol. 11, no. 2, 2025, pp. 133-148. |
| APA | Azizpour Y, Salehi S, Karimi A, Akbarpour S (2025). Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences. Journal of Biostatistics and Epidemiology, 11(2), 133-148. |
| Chicago | Azizpour Y, Salehi S, Karimi A, Akbarpour S. "Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences." Journal of Biostatistics and Epidemiology 11, no. 2 (2025): 133-148. |
| Harvard | Azizpour Y et al. (2025) 'Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences', Journal of Biostatistics and Epidemiology, 11(2), pp. 133-148. |
| Vancouver | Azizpour Y, Salehi S, Karimi A, Akbarpour S. Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences. Journal of Biostatistics and Epidemiology. 2025;11(2):133-148. |
| BibTex | @article{ author = {Azizpour Y and Salehi S and Karimi A and Akbarpour S}, title = {Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences}, journal = {Journal of Biostatistics and Epidemiology}, volume = {11}, number = {2}, pages = {133-148}, year = {2025} } |
| RIS | TY - JOUR AU - Azizpour Y AU - Salehi S AU - Karimi A AU - Akbarpour S TI - Iran’S Hypertension and Diabetes Mellitus Surveillance System and Its Implementation Challenges: A Case Study of Tehran University of Medical Sciences JO - Journal of Biostatistics and Epidemiology VL - 11 IS - 2 SP - 133 EP - 148 PY - 2025 ER - |